Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

(2021) Stephanie Lheureux et al.   LANCET

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells

(2021) Astrid Murumägi et al.   Translational Oncology

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

(2021) Anthony Letai et al.   CANCER CELL

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

(2021) Disha Malani et al.   Cancer Discovery

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

(2021) Christoph Kornauth et al.   Cancer Discovery

Breeze: an integrated quality control and data analysis application for high-throughput drug screening

(2020) Swapnil Potdar et al.   BIOINFORMATICS

SciPy 1.0: fundamental algorithms for scientific computing in Python

(2020) Pauli Virtanen et al.   NATURE METHODS

The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer

(2020) Ludivine Dion et al.   Journal of Clinical Medicine

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

(2020) Keith T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

Mucinous Ovarian Carcinoma

(2019) Philippe Morice et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of NRG1 Gene Fusions in Solid Tumors

(2019) Sushma Jonna et al.   CLINICAL CANCER RESEARCH

SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors

(2019) Hengyu Lu et al.   MOLECULAR CANCER THERAPEUTICS

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity

(2019) Oded Kopper et al.   NATURE MEDICINE

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells

(2019) Kimmo Kettunen et al.   EUROPEAN UROLOGY

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

(2019) W. Larry Gluck et al.   INVESTIGATIONAL NEW DRUGS

Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers

(2018) Alexander Drilon et al.   Cancer Discovery

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer

(2018) Christoph Heining et al.   Cancer Discovery

OUP accepted manuscript

(2018)   Database-The Journal of Biological Databases and Curation

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells

(2018) Khalid Saeed et al.   INTERNATIONAL JOURNAL OF CANCER

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

(2018) Carmine Fedele et al.   Cancer Discovery

Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids

(2018) Sarah J. Hill et al.   Cancer Discovery

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

(2018) Markus Mayrhofer et al.   Genome Medicine

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer

(2017) Khalid Saeed et al.   EUROPEAN UROLOGY

Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens

(2017) Xuefeng Liu et al.   Nature Protocols

High grade serous ovarian carcinomas originate in the fallopian tube

(2017) S. Intidhar Labidi-Galy et al.   Nature Communications

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine

(2017) Chantal Pauli et al.   Cancer Discovery

Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing

(2017) Muntasir Mamun Majumder et al.   Oncotarget

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

(2017) David P. Kodack et al.   Cell Reports

Low-grade serous carcinoma of the ovary or peritoneum

(2016) D. M. Gershenson   ANNALS OF ONCOLOGY

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

(2016) S Eldfors et al.   LEUKEMIA

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells

(2016) Prson Gautam et al.   Molecular Cancer

Consistency in drug response profiling

(2016) John Patrick Mpindi et al.   NATURE

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

(2016) Tracy L. Stockley et al.   Genome Medicine

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors

(2016) Marian H. Harris et al.   JAMA Oncology

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

From drug response profiling to target addiction scoring in cancer cell models

(2015) Bhagwan Yadav et al.   Disease Models & Mechanisms

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

(2015) Clare L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap

(2015) Tauno Metsalu et al.   NUCLEIC ACIDS RESEARCH

Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer

(2015) Rosemary D. Cress et al.   OBSTETRICS AND GYNECOLOGY

ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

(2014) Camilo Guzmán et al.   PLoS One

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

(2014) Bhagwan Yadav et al.   Scientific Reports

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

(2014) Charity W Law et al.   GENOME BIOLOGY

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

Use of Reprogrammed Cells to Identify Therapy for Respiratory Papillomatosis

(2012) Hang Yuan et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

(2011) Xuefeng Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

(2010) Qing Sheng et al.   CANCER CELL